Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder

Withdrawn before enrolling · Phase 4 · Has a placebo group

Conditions studied: Opioid-use Disorder, Suicidal Ideation

In brief

The study aims to examine the effect of buprenorphine on suicidal ideation in individuals with opioid use disorder, and to investigate the functional brain activity related to its potential anti-suicidal effect.

Key facts

Study ID

NCT04234516

Run by

New York State Psychiatric Institute

People needed

0

Starts

2020-01-20

Expected to finish

2021-06-10

Last updated by the study team

2021-06-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-55 years old
• Current opioid use disorder (mild, moderate or severe)
• Seeking treatment for opioid use disorder and willing to accept agonist-based therapy and be stabilized on buprenorphine when study is over
• Active suicidal ideation
• Participant must agree to voluntary admission to New York State Psychiatric Institute (NYSPI) inpatient research unit with confirmed bed availability
• Capacity to provide informed consent

You may not qualify if…

• Presence of chronic pain of sufficient severity as to require ongoing pain management with opioids
• Current active psychosis or mania
• Current moderate-severe alcohol, benzodiazepine, or other drug use likely to require a medical detoxification
• Unstable epilepsy or other neurological disorder
• A history of prior head trauma with evidence of cognitive impairment. Participants who endorse a history of prior head trauma will be administered Trail-making A and B test. Those who score 1.5 standard deviations below the mean on Trail- making A or B will be excluded from study participation
• Active significant medical illness that, in the opinion of the study physician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease)
• Liver Function Tests (ALT, AST) greater than 5 times upper limit of normal
• On methadone-maintenance therapy
• Contraindication to any study treatment (e.g., Known allergy or sensitivity to buprenorphine)
• Pending legal action or other reasons that might prevent an individual from completing the study
• If female, currently pregnant or breastfeeding, or planning on conception
• Inadequate understanding of English
• Metal implants or paramagnetic objects contained within the body (including heart pacemaker, shrapnel, or surgical prostheses) which may present a risk to the subject or interfere with the MRI scan
• Claustrophobia significant enough to interfere with MRI scanning
• Weight over 350 lbs or inability to fit into MRI scanner

Where it is running

• New York State Psychiatric Institute — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.